Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Here's the beginning of a new podcast with my friend, Dr. Gerard Silvestri, who is a pulmonologist at the Medical University of South Carolina (MUSC) in Charleston. He did a live webinar with us a few months ago, co-sponsored by GRACE and the LUNGevity Foundation, on the topic of pulmonary complications from lung cancer treatment, with the first part of his presentation focusing on chemotherapy-induced pneumonitis (lung inflammation), which we haven't spent a lot of time talking about.
Here's the first podcast from his presentation, in both video and audio podcast formats, as well as the transcript and figures from the program.
Dr. Silvestri Pulm Complications LC Treatment Chemo Pneumonitis Audio Podcast
Dr. Silvestri Pulm Complications LC Treatment Chemo Pneumonitis Transcript
Dr. Silvestri Pulm Complications LC Treatment Chemo Pneumonitis Figs
We'll continue with further discussion of lung-related complications from treatment of lung cancer in the next podcast, which will cover targeted therapies.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: